Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
46.17 USD | -2.02% | -12.70% | -23.22% |
Apr. 17 | Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65 | MT |
Apr. 17 | Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.22% | 8.57B | |
-2.83% | 102B | |
+1.75% | 96.07B | |
-1.80% | 21.66B | |
-17.68% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.06% | 13.79B | |
-0.23% | 13.33B | |
+19.30% | 10.94B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- Legend Biotech Says Phase 3 Trial of Multiple Myeloma Drug Candidate Meets Primary Endpoint; Shares Rise